![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » DOJ Charges Former Executives of Insys Therapeutics, Puma Biotechnology
DOJ Charges Former Executives of Insys Therapeutics, Puma Biotechnology
October 6, 2016
The Department of Justice indicted two executives from separate pharmaceutical companies, alleging that one engaged in a kickback scheme and the other relied on confidential study findings to purchase and sell stock.
Jeffrey Pearlman, a former district sales manager for Insys Therapeutics, was arrested and charged with engaging in a kickback scheme to boost sales of the company’s only FDA-approved product, Subsys, between September 2012 and December 2015.
Pearlman is the third employee to face charges in connection with his alleged involvement in a sham speaker program that paid doctors, nurses and physician assistants thousands of dollars as an incentive to prescribe the fentanyl sublingual spray.
Upcoming Events
-
21Oct